Company
Headquarters: Xiamen, China
Employees: 840
CN¥8.47 Billion
CNY as of July 1, 2025
US$1.18 Billion
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $162.07 B |
| Danaher | $144.92 B |
| Siemens Healthineers AG | $64.17 B |
| Lonza Group Ltd | $49.67 B |
| IDEXX Laboratories, Inc. | $43.99 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥1.15 B |
| EBITDA | CN¥353.5 M |
| Gross Profit TTM | CN¥957.7 M |
| Profit Margin | 24.50% |
| Operating Margin | 32.43% |
| Quarterly Revenue Growth | 16.60% |
Amoy Diagnostics Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300685 wb_incandescent